Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | HRH1 | P35367 | 5/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | HTR2B | P41595 | 3/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | TEK | Q02763 | 1/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138082 | 1.00 | NPC1 (0.60) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL1138342 | 0.99 | HRH1 (0.58) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| Hydrochloric Acid SCHEMBL1138343 | 0.99 | HRH1 (0.58) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL1138165 | 0.93 | LMNA (0.60) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL1138127 | 0.93 | HRH1 (0.69) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL5623785 | 0.93 | HRH1 (0.69) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL5623789 | 0.93 | HRH1 (0.69) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL1138130 | 0.93 | HRH1 (0.69) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL1138215 | 0.93 | HRH1 (0.69) | NPC1HRH1SLC6A2HTR2ASLC6A4 | |
| SCHEMBL1138170 | 0.93 | LMNA (0.60) | NPC1HRH1SLC6A2HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487810-B9 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2011-02-23 | — | — | EP | claimed |
| EP-1487810-B1 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-02-17 | — | — | EP | claimed |
| US-7297697-B2 | with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-11-20 | — | — | US | claimed |
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | US | claimed |
| EP-1487810-B9 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2011-02-23 | — | — | EP | disclosed |
| EP-1487810-B1 | 4-(DIARYLMETHYL)-1-PIPERAZINYL DERIVATIVES | SUN PHARMA ADVANCED RES CO LTD (IN) | 2010-02-17 | — | — | EP | disclosed |
| US-7297697-B2 | with alkenyl moiety substituted at the 1-position of the piperazine unit; useful in the treatment of histamine mediated diseases | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107393-A1 | 4-(diarylmethyl)-1-piperazinyl derivatives | NPY2R, NPY1R, CBR3 | NPC1 1689/4885HRH1 111/4885SLC6A2 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.